The rationale for the aggressive progression of MASLD in patients with type 2 diabetes

The rationale for the aggressive progression of MASLD in patients with type 2 diabetes

Saved in:

Bibliographic Details
Main Authors:	Valeria Michelle Fernández-Garibay, Norberto C. Chavez-Tapia
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	Annals of Hepatology
Subjects:	steatotic liver disease NAFLD (non-alcoholic fatty liver disease) NASH (non-alcoholic steatohepatitis) liver-related mortality adverse-liver outcomes liver disease
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268125000043
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results
by: V. T. Ivashkin, et al.
Published: (2015-12-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01)

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion
by: V. V. Tsukanov, et al.
Published: (2023-11-01)

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)

Non-invasive methods for diagnosing portal hypertension and variceal bleeding due to liver cirrhosis secondary to NAFLD/MASLD: systematic review
by: Nebyu Yonas Shanka, et al.
Published: (2025-01-01)

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
by: Gong Feng, et al.
Published: (2025-03-01)

Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Jessica M. Rubino, et al.
Published: (2025-01-01)

Profile of Children With Non-alcoholic Fatty Liver Disease Referred to a Hospital in Iran
by: Amin Ghanbari, et al.
Published: (2024-12-01)

Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease
by: V. T. Ivashkin, et al.
Published: (2022-12-01)

Liver macrophage activation: Relation with hepatic histopathological changes in patients with metabolic associated steatotic liver disease
by: Doaa H. Hegazy, et al.
Published: (2024-06-01)

Methodical approaches in experimental modelling of non-alcoholic fatty liver disease
by: N. V. Bivalkevich, et al.
Published: (2015-09-01)

Perioperative treatment with cilostazol reverses steatosis and improves liver regeneration after major hepatectomy in a steatotic rat model
by: Sebastian Holländer, et al.
Published: (2025-01-01)

Epidemiologic features of non-alcoholic fatty liver disease in Russia
by: O. M. Drapkina, et al.
Published: (2014-10-01)

Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease
by: Aleksey O. Bueverov
Published: (2019-03-01)

Mediterranean diet improves liver health but does not protect against azoxymethane-induced colon tumorigenesis compared to Western diet in A/J mice
by: Weimin Guo, et al.
Published: (2025-03-01)

Associations between Chinese Visceral Adiposity Index and the Risk of Metabolic Dysfunction-associated Steatotic Liver Disease and Liver Fibrosis: A Large Cross-sectional Study
by: Hui Liu, et al.
Published: (2025-01-01)

Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review
by: Hongcai Li, et al.
Published: (2025-02-01)

Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

Detectability of Liver Steatosis and Fibrosis with Transient Elastography and Controlled Attenuation Parameter in Residents of St. Petersburg
by: V. P. Kovyazina, et al.
Published: (2021-04-01)

Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH)
by: Zobair M. Younossi, et al.
Published: (2025-03-01)

Non-Alcoholic Fatty Liver Disease, Bile Acids and Intestinal Microbiota
by: R. V. Maslennikov, et al.
Published: (2018-09-01)

Ultrasound radiomics-based logistic regression model for fibrotic NASH
by: Fei Xia, et al.
Published: (2025-02-01)

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01)

Intrahepatic Cholestasis in Non-Alcoholic Fatty Liver Disease: Pathogenesis and Role of Ademetionine in Treatment
by: Ye. N. Shirokova
Published: (2023-08-01)

Improvement of non-alcoholic fatty liver disease treatment
by: P. I. Seliverstov, et al.
Published: (2014-10-01)

Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B
by: S. N. Batskikh, et al.
Published: (2020-09-01)

Dose-response relationship between the fatty liver index and asthma risk: NHANES 2001~2018
by: Tengfei Sun, et al.
Published: (2025-02-01)

Histopathological analysis of the liver in hypercholesterolemia rats treated with Dillenia serrata fruits
by: Tien, et al.
Published: (2022-12-01)

Association between non-alcoholic fatty liver disease and progression of abdominal aortic aneurysm: a multicenter study
by: Ximing Wang, et al.
Published: (2025-01-01)

Treatment of HCV infection in patients with steatotic liver disease
by: Robert Flisiak, et al.
Published: (2024-07-01)

Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
by: Roger F. Butterworth, et al.
Published: (2019-03-01)

The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates
by: Ruike Yan, et al.
Published: (2025-01-01)

The value of sex hormones and sex hormone-binding globulin in metabolic dysfunction-associated fatty liver disease among boys with obesity
by: Ying Wang, et al.
Published: (2025-02-01)

Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
by: A. E. Bagriy, et al.
Published: (2021-06-01)

Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
by: Masahiro Kikuchi, et al.
Published: (2024-09-01)

Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01)

Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma
by: Melchor Alpízar Salazar, et al.
Published: (2025-01-01)

The Role of the Microbiome and Intestinal Mucosal Barrier in the Development and Progression of Non-Alcoholic Fatty Liver Disease
by: T. S. Krolevets, et al.
Published: (2020-12-01)

Global research trends in Chinese medicine for the treatment of non-alcoholic fatty liver disease (NAFLD): A bibliometric study
by: Kangjie li, et al.
Published: (2025-03-01)